Regression of established liver tumor induced by monoepitopic peptide-based immunotherapy

Journal of Immunology

Volumn 173, Issue 8, 2004, Pages 4882-4888

  Belnoue, Elodie ^a,e   Guettier, Catherine ^b   Kayibanda, Michèle ^a   Le Rond, Solène ^a   Crain Denoyelle, Anne Marie ^a   Marchiol, Carmen ^a   Ziol, Marianne ^c,d   Fradelizi, Didier ^a   Rénia, Laurent ^a   Viguier, Mireille ^a,f  

^a Hôpital Cochin ^*  (France)

^b HÔPITAL PAUL BROUSSE   (France)

^c HÔPITAL JEAN VERDIER   (France)

^d UFR SMBH   (France)

^e UNIVERSITY OF GENEVA   (Switzerland)

^f INSTITUT COCHIN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINYLLYSYLGLYCYLVALYLASPARAGINYLLYSYLGLUTAMYLTYROSYLLEUCINE; EPITOPE; GLYCYLGLUTAMINYLGLYCYLISOLEUCYLASPARAGINYLASPARAGINYLLEUCYLASPARTYLASPARAGINYLLEUCINE; PEPTIDE; UNCLASSIFIED DRUG; VALYLSERYLALANYLISOLEUCYLASPARAGINYLASPARAGINYLTYROSYLALANYLGLUTAMINYLLYSYLLEUCINE; VALYLVALYLTYROSYLASPARTYLPHENYLALANYLLEUCYLLYSYLCYSTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL TRANSPLANTATION; CELLULAR IMMUNITY; CONTROLLED STUDY; EXPERIMENTAL MODEL; IMMUNIZATION; IMMUNOTHERAPY; LIVER PARENCHYMA; LIVER TUMOR; LYMPHOCYTE DEPLETION; MALE; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; SPLEEN; T LYMPHOCYTE; TRANSGENIC MOUSE; TUMOR GROWTH; TUMOR REGRESSION;

EID: 6344258245     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.173.8.4882     Document Type: Article

References (35)

1. Liang, T. J., L. J. Jeffers, K. R. Reddy, M. De Medina, I. T. Parker, H. Cheinquer, V. Idrovo, A. Rabassa, and E. R. Schiff. 1993. Viral pathogenesis of hepatocellular carcinoma in the United States. Hepatology 18:1326.
2. Levin, B., and C. Amos. 1995. Therapy of unresectable hepatocellular carcinoma. N. Engl. J. Med. 332:1294.
3. Pardoll, D. 2003. Does the immune system see tumors as foreign or self? Annu. Rev. Immunol. 21:807.
4. Shastri, N., S. Schwab, and T. Serwold. 2002. Producing nature's gene-chips: the generation of peptides for display by MHC class I molecules. Annu. Rev. Immunol. 20:463.
5. Dudley, M. E., and S. A. Rosenberg. 2003. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat. Rev. Cancer 3:666.
6. Dubois, N., M. Bennoun, I. Allemand, T. Molina, G. Grimber, M. Daudet-Monsac, R. Abelanet, and P. Briand. 1991. Time-course development of differentiated hepatocarcinoma and lung metastasis in transgenic mice. J. Hepatol. 13:227.
7. Zheng, X., J. X. Gao, H. Zhang, T. L. Geiger, Y. Liu, and P. Zheng. 2002. Clonal deletion of simian virus 40 large T antigen-specific T cells in the transgenic adenocarcinoma of mouse prostate mice: an important role for clonal deletion in shaping the repertoire of T cells specific for antigens overexpressed in solid tumors. J. Immunol 169:4761.
8. + T cell-based immunotherapy interferes with liver tumor progression in a transgenic mouse model. J. Immunol. 161:5133.
9. Manickan, E., J. Satoi, T. C. Wang, and T. J. Liang. 2001. Conditional liver-specific expression of simian virus 40 T antigen leads to regulatable development of hepatic neoplasm in transgenic mice. J. Biol. Chem. 276:13989.
10. Baratin, M., M. Ziol, R. Romieu, M. Kayibanda, F. Gouilleux, P. Briand, P. Leroy, H. Haddada, L. Rénia, M. Viguier, et al. 2001. Regression of primary hepatocarcinoma in cancer-prone transgenic mice by local interferon-γ delivery is associated with macrophages recruitment and nitric oxide production. Cancer Gene Ther. 8:193.
11. Sette, A., A. Vitiello, B. Reherman, P. Fowler, R. Nayersina, W. M. Kast, C. J. Melief, C. Oseroff, L. Yuan, and J. Ruppert. 1994. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J. Immunol. 153:5586.
12. + T lymphocytes induced by peptide immunization: an ex vivo analysis. Int. Immunol. 10:1273.
13. Gupta, S., N. R. Chowdhury, R. Jagtiani, K. Gustin, E. Aragona, D. A. Shafritz, J. R. Chowdhury, and R. D. Burk. 1990. A novel system for transplantation of isolated hepatocytes utilizing HBsAg-producing transgenic donor cells. Transplantation 50:472.
14. Ponder, K. P., S. Gupta, F. Leland, G. Darlington, M. Finegold, J., F. D. Ledley, J. R. Chowdhury, and S. L. Woo. 1991. Mouse hepatocytes migrate to liver parenchyma and function indefinitely after intrasplenic transplantation. Proc. Natl. Acad. Sci. USA 88:1217.
15. Romieu, R., V. Lacabanne, M. Kayibanda, B. Antoine, M. Bennoun, S. Chouaib, J. G. Guillet, and M. Viguier. 1997. Critical stages of tumor growth regulation in transgenic mice harboring a hepatocellular carcinoma revealed by distinct patterns of tumor necrosis factor-α and transforming growth factor-β mRNA production. Int. Immunol. 9:1405.
16. Mylin, L. M., R. H. Bonneau, J. D. Lippolis, and S. S. Tevethia. 1995. Hierarchy among multiple H-2b-restricted cytotoxic T-lymphocyte epitopes within simian virus 40 T antigen. J. Virol. 69:6665.
17. Baratin, M., M. Kayibanda, M. Ziol, R. Romieu, J. P. Briand, J. G. Guillet, and M. Viguier. 2002. Amino acid modifications in the wild type sequence p53 232-240 overcome the poor immunogenicity of this self tumour epitope. J. Pept. Sci. 8:327.
18. Morel, A., A. De la Coste, N. Fernandez, A. Berson, M. Kaybanda, T. Molina, P. Briand, H. Haddada, J. G. Guillet, B. Antoine, et al. 1998. Does preventive vaccination with engineered tumor cells work in cancer-prone transgenic mice? Cancer Gene Ther. 5:92.
19. Tatsumi, T., T. Takehara, T. Kanto, T. Miyagi, N. Kuzushita, Y. Sugimoto, M. Jinushi, A. Kasahara, Y. Sasaki, M. Hori, et al. 2001. Administration of interleukin-12 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines in mouse hepatocellular carcinoma. Cancer Res. 61:7563.
20. Schmitz, V., M. Barajas, L. Wang, D. Peng, M. Duarte, J. Prieto, and C. Qian. 2001. Adenovirus-mediated CD40 ligand gene therapy in a rat model of orthotopic hepatocellular carcinoma. Hepatology 34:72.
21. Nakamoto, Y., L. G. Guidotti, C. V. Kuhlen, P. Fowler, and F. V. Chisari. 1998. Immune pathogenesis of hepatocellular carcinoma. J. Exp. Med. 188:341.
22. Wolschek, M. F., C. Thallinger, M. Kursa, V. Rossler, M. Allen, C. Lichtenberger, R. Kircheis, T. Lucas, M. Willheim, W. Reinisch, et al. 2002. Specific systemic nonviral gene delivery to human hepatocellular carcinoma xenografts in SCID mice. Hepatology 36:1106.
23. Rénia, L., M. M. Rodrigues, and V. Nussenzweig. 1994. Intrasplenic immunization with infected hepatocytes: a mouse model for studying protective immunity against malaria pre-erythrocytic stage. Immunology 82:164.
24. Appleman, L. J., and V. A. Boussiotis. 2003. T cell anergy and costimulation. Immunol. Rev. 192:161.
25. Ochsenbein, A. F., P. Klenerman, U. Karrer, B. Ludewig, M. Pericin, H. Hengartner, and R. M. Zinkernagel. 1999. Immune surveillance against a solid tumor fails because of immunological ignorance. Proc. Natl. Acad. Sci. USA 96:2233.
26. Ochsenbein, A. F., S. Sierro, B. Odermatt, M. Pericin, U. Karrer, J. Hermans, S. Hemmi, H. Hengartner, and R. M. Zinkernagel. 2001. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 411:1058.
27. Kim, J., R. L. Modlin, R. L. Moy, S. M. Dubinett, T. McHugh, B. J. Nickoloff, and K. Uyemura. 1995. IL-10 production in cutaneous basal and squamous cell carcinomas: a mechanism for evading the local T cell immune response. J. Immunol. 155:2240.
28. + regulatory T cells in a colorectal carcinoma patient is mediated by transforming growth factor-β. Cancer Res. 62:5267.
29. + immunoregulatory cells. J. Immunol. 167:1137.
30. Lacabanne, V., M. Viguier, R. Romieu, M. Kayibanda, F. Connan, S. Sermet, B. Antoine, J. G. Guillet and J. Choppin. 1998. Differential presentation of endogenously processed cytotoxic T lymphocyte epitopes by mouse hepatocarcinoma cell lines induced by SV40 large T antigen. Int. Immunol 10:463.
31. + T-lymphocyte responses to multiple epitopes from simian virus 40 (SV40) large T antigen in C57BL/6 mice immunized with SV40, SV40 T-antigen transformed cells, or vaccinia virus recombinants expressing full-length T antigen or epitope minigenes. J. Virol. 74:6922.
32. Speiser, D. E., R. Miranda, A. Zakarian, M. F. Bachmann, K. McKall-Faienza, B. Odermatt, D. Hanahan, R. M. Zinkernagel, and P. S. Ohashi. 1997. Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: implications for immunotherapy. J. Exp. Med. 186:645.
33. + T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci. USA 99:16168.
34. Dudley, M. E., J. R. Wunderlich, P. F. Robbins, J. C. Yang, P. Hwu, D. J. Schwartzentruber, S. L. Topalian, R. Sherry, N. P. Restifo, A. M. Hubicki, et al. 2002. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298:850.
35. + T cells. J. Exp. Med. 198:569.